Hepatitis B and C testing activities, needs, and priorities in the EU/EEA
Hepatitis B and C virus infections are associated with a considerable burden of disease in Europe.
ECDC undertook a survey to assess needs and priorities prior to developing guidance on testing and screening for hepatitis B and C in the EU/EEA, and to update the existing evidence on the burden of HBV/HCV morbidity and mortality across EU/EEA Member States. The purpose of this work was to provide a baseline situation assessment to inform the guidance development process, and to assess the availability and feasibility of collecting additional morbidity and mortality data from EU/EEA Member States.
The sustainable development goals and hepatitis B and C in the EU/EEA
29 Mar 2021 - In order to monitor progress towards the United Nations Sustainable Development Goals 2030 target to combat viral hepatitis, this report provides data on hepatitis B and C prevention, incidence, diagnosis, treatment, cure/viral suppression, and mortality in European Union/European Economic Area (EU/EEA) countries with data collected in 2019.
Hepatitis B and C testing in the EU/EEA: progress in reaching the elimination targets
26 Mar 2021 - This brief will present a snapshot of hepatitis B and C testing in the European Union/European Economic Area (EU/EEA), discussing progress made towards the European action plan 2020 testing target, focussing on key populations and settings for testing, barriers to testing, and testing policies.
Prevention of hepatitis B and C in the EU/EEA and the UK
24 Nov 2020 - Urgent action is required to improve efforts to prevent hepatitis B and C infections in the EU/EEA and the UK if the region is to meet the 2020 targets for the elimination of viral hepatitis as a serious threat to public health. Significant gaps in the reported data in relation to prevalence and prevention of HBV and HCV in EU/EEA and the UK present a major challenge to monitoring progress towards the targets for elimination of hepatitis.